Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study

by Alex C. Spyropoulos MD, Concetta Lipardi MD, PhD, Jianfeng Xu PhD, Wentao Lu PhD, Eunyoung Suh PhD, Zhong Yuan MD, PhD, Bennett Levitan MD, PhD, Chiara Sugarmann BSN, MSHS, Yoriko De Sanctis MS, Theodore E. Spiro MD, Elliot S. Barnathan MD, Gary E. Raskob PhD
Published 2019-11-01

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis

by Concetta Lipardi MD, PhD, C. Gregory Elliott MD, Chiara L. Sugarmann BSN, MSHS, Lloyd Haskell MD, Alex C. Spyropoulos MD, Gary E. Raskob PhD, Jianfeng Xu PhD, Wentao Lu PhD, Jessica Marsigliano BS, Theodore Spiro MD, Zhong Yuan MD, PhD, Shujian Wu MD, PhD, Elliot S. Barnathan MD
Published 2021-10-01